Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide,
docetaxel, and zoledronic acid, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug
(combination chemotherapy) may kill more tumor cells. It is not yet known whether combination
chemotherapy is more effective when given together with zoledronic acid in treating patients
with breast cancer.
PURPOSE: This randomized phase III trial is studying giving doxorubicin hydrochloride
together with cyclophosphamide and docetaxel to see how well it works with or without
zoledronic acid in treating patients with large resectable or locally advanced breast cancer.